GSK Just Paid $10.6 Billion for This Precision Oncology Bet — Here’s What It Signals
The Nuvalent acquisition is the biggest biopharma deal of the week — and it’s rewriting the playbook for lung cancer investing.
The Nuvalent acquisition is the biggest biopharma deal of the week — and it’s rewriting the playbook for lung cancer investing.
Oracle’s Q4 earnings hit after close — and the derivatives market is positioning for a major swing in either direction.
Marvell Technology is no longer flying under the radar, and the case for owning it goes well beyond one speech.
The cybersecurity leader crossed $5 billion in ARR and announced a 4-for-1 stock split. The post-earnings selloff may be the setup.
A $10.44 EPS print, 33% revenue growth, and a $1.49 trillion market cap — and the market keeps selling rallies. The options flow has been telling you why.
META’s post-earnings selloff is one of the most analytically interesting disconnects in the Magnificent 7 right now.
Brent crude, the Strait of Hormuz, and ExxonMobil’s 24% YTD run — the oil trade in 2026 is unlike anything since the 1970s.
Record equities, a four-year-high M&A backlog, and a SpaceX IPO mandate — GS is firing on almost every cylinder. Almost.
CRM delivered record Q1 FY2027 results powered by Agentforce — but the price action tells a more complicated story that options traders were already pricing in.
After a $1 trillion semiconductor wipeout, the options market is repricing the entire custom-ASIC story